DFX Intelligence
Family Office Intelligence
A continuously maintained graph of U.S. family offices: identity, team, observed investments, public holdings, relationships and dated signals of change. Facts, inferences and estimates are labelled as such, with the source and the date, on every row. Unknown is printed as unknown.
Family office profile
Apeiron
Headquartered in Sliema, Malta, and structured as Christian Angermayer's family office and merchant-banking businessSingle family office (probable)identity confidence 70%Top 500 by research priorityapeiron-investments.com
Why this class: a filing by a third party describes it as a single family office (cited).
Verified Sep 16, 2026 (2 days ago)
Last observed Sep 16, 2026 · 28 observations · 4 sources
1 people · 3 investments · 0 public positions · 6 events
Identity
70
high
Data depth
75
high
Freshness
100
high
Active deployment
25
moderate
Direct investing
45
elevated
External managers
0
low
Private markets
0
low
Sponsor-friendly
0
low
Real estate
0
low
Co-investment
90
high
Contactability
25
moderate
Mandate confidence
50
elevated
Twelve separate dimensions, each 0 to 100 from listed components. There is no single family office score; the components are in the evidence section.
Overview
Profile completeness 47% (high value, high value shallow; the most valuable missing fact is mandate)
identityclassificationwealth origincapital-scale evidencepeoplecontactsmandatedirect investmentsfund relationshipsco-investorssponsor relationshipsreal estatepublic holdingsrecent eventsprovenancefreshness
- Classification
- Single family office (probable)
- Description
- Apeiron Investment Group is a discretionary investment firm founded and owned by serial entrepreneur and investor Christian Angermayer.
- Headquarters
- Headquartered in Sliema, Malta, and structured as Christian Angermayer's family office and merchant-banking business
- Office address
- unknown
- Business phone
- unknown
- Website
- apeiron-investments.com
- Year established
- unknown
- Assets under management
- unknown
- Capital scale
- Reported office AUM: unknown. No public number of any kind.
Classification history
- Sep 14, 2026Single family office (probable) 70%a filing by a third party describes it as a single family office (cited)Fact
- Sep 14, 2026Candidate 25%no rule matched; held as a candidate pending researchInference
Family and wealth origin
- Family served
- Angermayer family
- Source of wealth
- Founder's wealth originated from co-founding biotech Ribopharma AG, which became a multimillion-dollar exit at age 25
- Operating company origin
- unknown
Team
| Person | Title | Responsibility | Business contact | Source |
|---|---|---|---|---|
| Christian Angermayer | Founder | Leadership · investment decisions | email: christian.angermayer@apeiron-investments.com (verified by provider, Sep 15, 2026) | sec.gov Fact |
Office contact points
Investment mandate
Stated (their words, cited)
No cited statement of mandate on the record.
Observed (from the investment record)
No investments on the record yet, so nothing is observed.
Inferred (regulatory shape and team)
Nothing to infer from.
- Invests directly
- Holds a 23.7% voting stake in atai Life Sciences N.V. via Ordinary Shares including PIPE-financing purchases
- Allocates to managers
- Beyond direct investing, also makes anchor LP commitments and takes GP stakes in emerging asset managers
- Asset classes
- unknown
- Sectors
- Investment thesis centers on psychedelics as a mental-health treatment category, among other frontier sectors
- Geography
- Holds stakes in publicly traded and private companies across the US, Germany, Canada and Australia
- Check size
- unknown
Direct investments
| Date | Company | Kind | Sector | Role | Amount | With | Source |
|---|---|---|---|---|---|---|---|
| Jul 1, 2025 | atai Life Sciences N.V. | Public company stake built via PIPE financings and open-market purchases | biopharma / mental health | lead · minority | $50.0M | Ferring Ventures S.A. (co investor), Ally Bridge Group (co investor), ADAR1 (co investor) | globenewswire.com Fact “co-led by Ferring Ventures S.A. and Apeiron Investment Group, the family office of atai Founder and Chairman Christian Angermayer.” |
| Sep 21, 2021 | Palo Santo | Direct investment | unknown | participant | unknown | none named | globenewswire.com Fact “Palo Santo is thrilled to be investing alongside Apeiron , re.Mind , and bm-t and looks forward to partnering with neurocare to guide the co” |
Fund and manager relationships
No fund commitment or manager relationship on the record. Commitment amounts are shown only when public.
Public stakes and holdings
Stakes the office filed (Schedule 13D, 13G, Section 16)
From EDGAR's index of the office's own filings. A 13D is a stake of 5% or more held with intent, a 13G one held passively, a Form 3, 4 or 5 the office as an insider of the issuer. The size of the stake is inside each filing and is not shown here.
| First filed | Issuer | Filed as | Filings |
|---|---|---|---|
| Jun 15, 2026 | Enhanced Group | Section 16 insider | ("Enhanced" or the "Company") (NYSE: ENHA ) today announced that it has entered into an agreement for a $50 million strategic equity financing via a private investment in public equity ("PIPE") financing transaction led by Apeiron Investment Group, the family office of Enhanced Co-Founder and Chairman Christian Angermayer, with participation from Co-Founder and CEO Maximilian Martin and leading global institutional investors. prnewswire.com |
Form 13F holdings
No 13F filing on the record for this office.
Real estate
No documented real estate ownership link. A property is attributed to an office only through a documented control relationship, never from a surname.
Co-investors
| Counterparty | Kind | Shared deals | First, last | Examples | Source |
|---|---|---|---|---|---|
| Ferring Ventures S.A. | organisation | 1 | Jul 1, 2025 | atai Life Sciences N.V. | globenewswire.com |
| ADAR1 | organisation | 1 | Jul 1, 2025 | atai Life Sciences N.V. | globenewswire.com |
| Ally Bridge Group | organisation | 1 | Jul 1, 2025 | atai Life Sciences N.V. | globenewswire.com |
- ADAR1 Jul 1, 2025 recurring (2) Fact globenewswire.com
- Ally Bridge Group Jul 1, 2025 recurring (2) Fact globenewswire.com
- Ferring Ventures S.A. Jul 1, 2025 recurring (2) Fact globenewswire.com
- ADAR1 Jul 1, 2025 recurring (2) Fact globenewswire.com
- Ally Bridge Group Jul 1, 2025 recurring (2) Fact globenewswire.com
- Ferring Ventures S.A. Jul 1, 2025 recurring (2) Fact globenewswire.com
Independent sponsor relationships
No cited relationship to an independent sponsor.
Signals and timeline
Most significant first: what kind of change it is, its size, whose change it is, and how recent. 6 events. 13F position changes are under Public stakes and holdings.
- Apr 22, 2026Office discoveredApeiron described on SEC filings as 'family office' (10-K, 424B4, DEF 14A, S-1, S-1/A)DiscoveryFactsec.gov
- Sep 14, 2026Classification changedApeiron: CANDIDATE_FAMILY_OFFICE -> PROBABLE_SFO (a filing by a third party describes it as a single family office (cited))ClassificationFactno URL
- Aug 14, 2025Fund commitment disclosedApeiron's atai Life Sciences stake reaches 23.7% of voting rightsFund relationshipsFactsec.gov
- Jul 1, 2025Direct investmentApeiron co-leads $50 million PIPE financing for atai Life SciencesDirect investmentsFactglobenewswire.com
- Jul 1, 2025Direct investmentApeiron invested in atai Life Sciences N.V.Direct investmentsFactglobenewswire.com
- Jan 1, 2018Direct investmentChristian Angermayer founds atai Life SciencesDirect investmentsFacten.wikipedia.org
Sources and evidence
Every observation behind this profile: the value, when it was effective, the source, the quote where there is one, and whether it is a fact, an inference or an estimate. 28 shown.
Score components
Freshness
+100 days since the newest source-dated fact or analyst verification (1 days)
Contactability
+15 named decision-makers (Christian Angermayer (Founder))
+10 verified business emails (1)
Data confidence
+10 website
+10 description
+10 stated mandate
+10 people
+15 investments
+20 independent sources (4 sources)
Active deployment
+25 dated private investments in last 24 months (atai Life Sciences N.V. (2025-07-01))
Exists confidence
+20 website
+30 independent sources (4 sources)
+30 analyst-verified
Research priority
+15 single family or family investment company
+9 direct investments on record
+10 deployed in last 24 months
+0 rank (127)
Mandate confidence
+30 mandate supported by observed investments
+20 stated mandate on the record
Identity confidence
+70 classification (PROBABLE_SFO (a filing by a third party describes it as a single family office (cited)))
Real estate propensity
no components; scored 0
Co investment propensity
+80 co-investors on the record (ADAR1; ADAR1; Ferring Ventures S.A.; Ally Bridge Group; Ally Bridge Group)
+10 participant in syndicated rounds
Family identity confidence
+60 wealth origin or operating company on the record
+40 family named (Angermayer family)
Private markets propensity
no components; scored 0
Current activity confidence
+50 dated private investment in 24 months
+25 a source-dated fact within 12 months (1 days)
External manager propensity
no components; scored 0
Direct investment propensity
+45 observed direct investments (3 on the record)
Independent sponsor propensity
no components; scored 0
| Fact | Value | Effective | Source | Class |
|---|---|---|---|---|
| Allocates to managers | Beyond direct investing, also makes anchor LP commitments and takes GP stakes in emerging asset managers “direct investments in innovative companies - both private and listed, as well as anchor LP investments combined with GP stakes in emerging asset managers.” | Sep 16, 2026 | DFX analyst research (General-assisted, every claim URL-cited) apeiron-investments.com | Fact |
| Allocates to managers | Beyond direct investing, also makes anchor LP commitments and takes GP stakes in emerging asset managers “direct investments in innovative companies - both private and listed, as well as anchor LP investments combined with GP stakes in emerging asset managers.” | Sep 15, 2026 | DFX analyst research (General-assisted, every claim URL-cited) apeiron-investments.com | Fact |
| Aum stated | Apeiron states it manages approximately $7 billion of internal and external capital “approximately $7 billion, both internal and external capital” | Sep 16, 2026 | DFX analyst research (General-assisted, every claim URL-cited) apeiron-investments.com | Fact |
| Aum stated | Apeiron states it manages approximately $7 billion of internal and external capital “approximately $7 billion, both internal and external capital” | Sep 15, 2026 | DFX analyst research (General-assisted, every claim URL-cited) apeiron-investments.com | Fact |
| Co invest behavior | Co-led atai Life Sciences' 2025 PIPE financing alongside Ferring Ventures S.A. “co-led by Ferring Ventures S.A. and Apeiron Investment Group, the family office of atai Founder and Chairman Christian Angermayer.” | Jul 1, 2025 | DFX analyst research (General-assisted, every claim URL-cited) globenewswire.com | Fact |
| Description | Apeiron Investment Group is a discretionary investment firm founded and owned by serial entrepreneur and investor Christian Angermayer. | Sep 16, 2026 | Family office and investment company websites (about, team, portfolio, news pages) apeiron-investments.com | Fact |
| Edgar fts discovery | family office | Apr 22, 2026 | SEC EDGAR full-text search (a filing sentence that says what an entity is, quoted with its URL) sec.gov | Fact |
| Family involvement | Christian Angermayer is Apeiron's controlling shareholder “Christian Angermayer is the controlling shareholder of Apeiron” | Aug 14, 2025 | DFX analyst research (General-assisted, every claim URL-cited) sec.gov | Fact |
| Family served | Angermayer family | Jun 8, 2021 | SEC EDGAR full-text search (a filing sentence that says what an entity is, quoted with its URL) sec.gov | Fact |
| Family wealth estimate | Forbes estimated Angermayer's net worth at $1.2 billion as of 2025 “As of 2025, he is estimated by Forbes to have a net worth of US$1.2 billion.” | Jan 1, 2025 | DFX analyst research (General-assisted, every claim URL-cited) en.wikipedia.org | Fact |
| Geographic mandate | Holds stakes in publicly traded and private companies across the US, Germany, Canada and Australia “His Malta-based Apeiron owns shares in several publicly traded firms and private companies in the U.S., Germany, Canada and Australia.” | Sep 16, 2026 | DFX analyst research (General-assisted, every claim URL-cited) forbes.com | Fact |
| Geographic mandate | Applies a global, multi-strategy approach with a primary focus on the United States “a global, multi-strategy investment approach, with a primary focus on the US.” | Sep 16, 2026 | DFX analyst research (General-assisted, every claim URL-cited) apeiron-investments.com | Fact |
| Geographic mandate | Applies a global, multi-strategy approach with a primary focus on the United States “a global, multi-strategy investment approach, with a primary focus on the US.” | Sep 15, 2026 | DFX analyst research (General-assisted, every claim URL-cited) apeiron-investments.com | Fact |
| Geographic mandate | Holds stakes in publicly traded and private companies across the US, Germany, Canada and Australia “His Malta-based Apeiron owns shares in several publicly traded firms and private companies in the U.S., Germany, Canada and Australia.” | Sep 15, 2026 | DFX analyst research (General-assisted, every claim URL-cited) forbes.com | Fact |
| Headquarters | Headquartered in Sliema, Malta, and structured as Christian Angermayer's family office and merchant-banking business “founding Apeiron Investment Group (based in Sliema, Malta), his family office and merchant-banking business” | Sep 16, 2026 | DFX analyst research (General-assisted, every claim URL-cited) en.wikipedia.org | Fact |
| Headquarters | Headquartered in Sliema, Malta, and structured as Christian Angermayer's family office and merchant-banking business “founding Apeiron Investment Group (based in Sliema, Malta), his family office and merchant-banking business” | Sep 15, 2026 | DFX analyst research (General-assisted, every claim URL-cited) en.wikipedia.org | Fact |
| Invests directly | Holds a 23.7% voting stake in atai Life Sciences N.V. via Ordinary Shares including PIPE-financing purchases “51,045,214 Ordinary Shares (including the 8,675,799 Ordinary Shares purchased in the PIPE Financing)” | Aug 14, 2025 | DFX analyst research (General-assisted, every claim URL-cited) sec.gov | Fact |
| Liquidity event | Sold his Ribopharma stake when the company merged into Alnylam Pharmaceuticals in 2003 “made his first millions cofounding biotech firm Ribopharma with his college professors; he sold his stake when it merged with Alnylam in 2003.” | Jan 1, 2003 | DFX analyst research (General-assisted, every claim URL-cited) forbes.com | Fact |
| Office type (stated) | single_family_office | Apr 22, 2026 | SEC EDGAR full-text search (a filing sentence that says what an entity is, quoted with its URL) sec.gov | Fact |
| Sectors | Investment thesis centers on psychedelics as a mental-health treatment category, among other frontier sectors “spearheading the renaissance of psychedelics as transformative treatments for mental health issues.” | Sep 16, 2026 | DFX analyst research (General-assisted, every claim URL-cited) apeiron-investments.com | Fact |
| Sectors | Investment thesis centers on psychedelics as a mental-health treatment category, among other frontier sectors “spearheading the renaissance of psychedelics as transformative treatments for mental health issues.” | Sep 15, 2026 | DFX analyst research (General-assisted, every claim URL-cited) apeiron-investments.com | Fact |
| Site mentions | direct_investments,real_estate | Sep 16, 2026 | Family office and investment company websites (about, team, portfolio, news pages) apeiron-investments.com | Fact |
| Source of wealth | Founder's wealth originated from co-founding biotech Ribopharma AG, which became a multimillion-dollar exit at age 25 “The business made Angermayer a multimillionaire at age 25.” | Sep 16, 2026 | DFX analyst research (General-assisted, every claim URL-cited) en.wikipedia.org | Fact |
| Source of wealth | Founder's wealth originated from co-founding biotech Ribopharma AG, which became a multimillion-dollar exit at age 25 “The business made Angermayer a multimillionaire at age 25.” | Sep 15, 2026 | DFX analyst research (General-assisted, every claim URL-cited) en.wikipedia.org | Fact |
| Website | apeiron-investments.com | Sep 15, 2026 | DFX model output (classification rules, scores, mandates, matches) apeiron-investments.com | Inference |
| Website read | site-fo-3 | Sep 16, 2026 | Family office and investment company websites (about, team, portfolio, news pages) apeiron-investments.com | Fact |
| Website search | not_found | Sep 14, 2026 | DFX model output (classification rules, scores, mandates, matches) no URL | Inference |
| Website title | Apeiron Investment Group | Sep 16, 2026 | Family office and investment company websites (about, team, portfolio, news pages) apeiron-investments.com | Fact |